[go: up one dir, main page]

BRPI0507903A - derivados de quinazolina e composição farmacêutica compreendendo os mesmos - Google Patents

derivados de quinazolina e composição farmacêutica compreendendo os mesmos

Info

Publication number
BRPI0507903A
BRPI0507903A BRPI0507903-9A BRPI0507903A BRPI0507903A BR PI0507903 A BRPI0507903 A BR PI0507903A BR PI0507903 A BRPI0507903 A BR PI0507903A BR PI0507903 A BRPI0507903 A BR PI0507903A
Authority
BR
Brazil
Prior art keywords
quinazoline derivatives
pharmaceutical composition
same
compounds
quinazoline
Prior art date
Application number
BRPI0507903-9A
Other languages
English (en)
Inventor
Young Bok Lee
Chang Ho Ahn
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of BRPI0507903A publication Critical patent/BRPI0507903A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS DE QUINAZOLINA E COMPOSIçãO FARMACêUTICA COMPREENDENDO OS MESMO. A presente invenção refere-se a derivados de quinazolina representados pela fórmula geral, sais farmacologicamente aceitáveis desses, e composições contendo tais compostos, que são descritos. Métodos para usar os compostos para tratamento de distúbios hiperproliferativos também são descritos.
BRPI0507903-9A 2004-02-19 2005-02-17 derivados de quinazolina e composição farmacêutica compreendendo os mesmos BRPI0507903A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54548704P 2004-02-19 2004-02-19
PCT/US2005/005151 WO2005080352A2 (en) 2004-02-19 2005-02-17 Quinazoline derivatives and therapeutic use thereof

Publications (1)

Publication Number Publication Date
BRPI0507903A true BRPI0507903A (pt) 2007-07-10

Family

ID=34886161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507903-9A BRPI0507903A (pt) 2004-02-19 2005-02-17 derivados de quinazolina e composição farmacêutica compreendendo os mesmos

Country Status (11)

Country Link
US (2) US7388014B2 (pt)
EP (2) EP1720841B1 (pt)
JP (1) JP4934432B2 (pt)
KR (1) KR100942865B1 (pt)
CN (1) CN1956966B (pt)
AU (1) AU2005214373B2 (pt)
BR (1) BRPI0507903A (pt)
CA (1) CA2557433C (pt)
ES (1) ES2554330T3 (pt)
MX (1) MXPA06009475A (pt)
WO (1) WO2005080352A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5237798B2 (ja) * 2005-06-23 2013-07-17 アレイ バイオファーマ、インコーポレイテッド ベンズイミダゾール化合物の調製方法
CA2652341A1 (en) * 2006-05-15 2007-11-22 Senex Biotechnology, Inc. Identification of cdki pathway inhibitors
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
CN101120945B (zh) * 2007-07-30 2010-11-24 浙江大学 8-芳胺基-3H-咪唑[4,5-g]喹唑啉类衍生物的用途
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
CA2805148C (en) * 2010-07-14 2016-01-19 Zhejiang Beta Pharma Inc. Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors
US20140309224A1 (en) * 2011-09-13 2014-10-16 Roninson Igor B TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
CN103086984A (zh) * 2011-11-03 2013-05-08 南京大学 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途
IN2014DN07954A (pt) 2012-03-13 2015-05-01 Basf Se
CN102659692B (zh) 2012-05-04 2014-04-09 郑州泰基鸿诺药物科技有限公司 双联厄洛替尼及其制备方法
CN102875570B (zh) * 2012-10-23 2015-11-04 浙江大学 喹唑啉衍生物及其制备方法和用途
EP2968360B1 (en) 2013-03-14 2021-01-20 ConverGene LLC Quinolinone derivatives for the inhibition of bromodomain-containing proteins
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
US20160221964A1 (en) 2013-09-16 2016-08-04 Basf Se Fungicidal pyrimidine compounds
WO2015040169A1 (en) * 2013-09-19 2015-03-26 Pierre Fabre Medicament Quinazoline derivatives and their use as dna methyltransferase inhibitors
CN104926798B (zh) * 2014-03-21 2019-06-18 江苏豪森药业集团有限公司 阿法替尼中间体的高纯度制备方法
ES3011058T3 (en) * 2015-11-25 2025-04-07 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
US10953016B2 (en) * 2017-01-30 2021-03-23 Shionogi & Co., Ltd. Solid dosage form containing quinazoline derivative
EP3897651A4 (en) * 2018-12-21 2022-09-21 University of Notre Dame du Lac DISCOVERY OF BD OXIDASE INHIBITORS FOR THE TREATMENT OF MYCOBACTERIAL DISEASES
WO2020219168A1 (en) 2019-04-24 2020-10-29 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof
KR102397359B1 (ko) * 2019-09-30 2022-05-11 한국화학연구원 4-아미노-퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
PH12022551585A1 (en) * 2019-12-27 2023-11-29 Lupin Ltd Substituted tricyclic compounds
TWI807787B (zh) * 2021-04-19 2023-07-01 大陸商昆藥集團股份有限公司 苯並嘧啶三環衍生物及製備方法和應用
CN116444443B (zh) * 2023-03-15 2025-09-05 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种苯甲酰-喹唑啉酮衍生物及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH492395A (de) 1966-04-26 1970-06-30 Sandoz Ag Mittel zur Bekämpfung von Pflanzenschädlingen und Verwendung des Mittels
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
GT198900008A (es) * 1988-01-29 1990-07-17 Derivados de quinolina, quinazolina y cinolina.
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU5108196A (en) * 1995-03-20 1996-10-08 Dr. Karl Thomae Gmbh Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
BR9709959A (pt) * 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
NZ330292A (en) 1996-08-30 2000-01-28 Kyowa Hakko Kogyo Company Ltd Imidazoquinazoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
CA2403365A1 (en) 2000-04-07 2001-10-18 Astrazeneca Ab Quinazoline compounds
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10042060A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
US20050187231A1 (en) 2005-08-25
KR20070028340A (ko) 2007-03-12
US7388014B2 (en) 2008-06-17
ES2554330T3 (es) 2015-12-18
WO2005080352A2 (en) 2005-09-01
AU2005214373B2 (en) 2011-07-28
MXPA06009475A (es) 2007-05-15
JP2007523177A (ja) 2007-08-16
CN1956966B (zh) 2012-04-18
CA2557433C (en) 2013-05-14
US20090030021A1 (en) 2009-01-29
CN1956966A (zh) 2007-05-02
US8404698B2 (en) 2013-03-26
KR100942865B1 (ko) 2010-02-17
EP2650286A1 (en) 2013-10-16
CA2557433A1 (en) 2005-09-01
EP1720841B1 (en) 2015-11-04
JP4934432B2 (ja) 2012-05-16
AU2005214373A1 (en) 2005-09-01
EP1720841A2 (en) 2006-11-15
WO2005080352A3 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
MX2009000884A (es) Derivados de piridizinona.
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
CY1110900T1 (el) Χημικες ενωσεις
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
EA201070786A1 (ru) Бензофуропиримидиноны
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
ATE523514T1 (de) Tricyclische triazolische verbindungen
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
BRPI0411308A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]